Xcout Intel
Gibson Oncology, LLC
Gibson Oncology is a biopharmaceutical company that develops treatments for brain cancer, focusing on its lead program involving the drug LMP744 for recurrent glioblastoma. The company is advancing LMP744 through clinical trials, including an NIH-conducted phase II trial for patients who have failed initial therapy.
Subscribe to see Gibson Oncology, LLC’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Gibson Oncology, LLC at a glance
Gibson Oncology, LLC is a biotechnology company headquartered in United States. It has raised at least $4M across the 2 funding rounds on record. Its most recent funding round raised $250,000 in July 2025. Xcout tracks 8 named people at Gibson Oncology, LLC, including Randall Riggs (Chief Executive Officer).
Gibson Oncology, LLC leadership
- Randall RiggsChief Executive Officer
- Clifford SolomonExecutive Officer
- Elizabeth RogersExecutive Officer
- Randall RiggsExecutive Officer
- Theodore SolomonExecutive Officer
- Mark BaganzDirector
2 more named people on record for Gibson Oncology, LLC, with roles, board committees and tenure — see the full roster →
Gibson Oncology, LLC funding rounds
At least $4M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $250,000 | — | |
| SEC Form D filing | $3.8M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Gibson Oncology, LLC competitors
A few of Gibson Oncology, LLC's closest competitors — see the full list of competitors and alternatives →
Dome Therapeutics is a preclinical biotechnology company developing a nanomedicine designed to target brain cancer stem cells that survive standard glioblastoma treatments and drive tumor recurrence. Using a proprietary nanoparticle delivery platform, the company aims to cross the blood-brain barrier to deliver therapeutic payloads directly to these treatment-resistant cells.
Treovir is a clinical-stage biotechnology company that develops therapies for pediatric brain tumors. Its lead product candidate, G207, is an oncolytic virus therapy currently undergoing clinical trials to treat conditions such as pediatric recurrent glioblastoma.
Neonc Technologies Holdings, Inc. specializes in pioneering molecular advancements aimed at improving the targeted administration of therapies for central nervous system disorders. The company's leading pipeline candidate, NEO100, is presently undergoing Phase 2a clinical trials for the treatment of glioblastoma. Additionally, NEO212, a unique molecular construct chemically linking the chemotherapeutic agent temozolomide with perillyl alcohol, has successfully concluded its preclinical evaluation. This enterprise, founded in 2023, operates from its base in Los Angeles, California.
Gate2Brain is a Barcelona-based biotechnology company focused on developing advanced pharmaceutical candidates to cross biological barriers for the treatment of brain tumors.
Reglagene Holding, Inc. is a biotechnology company developing brain-penetrant oral therapies for central nervous system oncology. Its lead small molecule candidate, RGN6024, is designed to cross the blood-brain barrier and evade efflux pumps to treat primary tumors and brain metastases.
Altido Therapeutics is a clinical-stage biotechnology company located in Waltham, Massachusetts that is advancing a dual-mechanism CAR-TEAM immunotherapy platform to treat glioblastoma.
Get Gibson Oncology, LLC's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Gibson Oncology, LLC in Xcout Intel
- 8 named people with titles, LinkedIn and board committees
- 2 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access